Liquidia (LQDA) Projected to Post Quarterly Earnings on Wednesday

Liquidia (NASDAQ:LQDA) is projected to release its earnings data before the market opens on Wednesday, March 12th. Analysts expect Liquidia to post earnings of ($0.39) per share and revenue of $4.60 million for the quarter.

Liquidia Stock Performance

NASDAQ:LQDA opened at $13.83 on Tuesday. The stock has a market cap of $1.17 billion, a P/E ratio of -8.48 and a beta of 0.07. Liquidia has a 1 year low of $8.26 and a 1 year high of $16.99. The stock has a 50-day simple moving average of $14.34 and a 200-day simple moving average of $11.90.

Insider Activity

In related news, insider Rajeev Saggar sold 2,445 shares of the stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $13.00, for a total value of $31,785.00. Following the completion of the transaction, the insider now directly owns 267,943 shares of the company’s stock, valued at $3,483,259. This represents a 0.90 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, General Counsel Russell Schundler sold 16,393 shares of the stock in a transaction that occurred on Tuesday, January 14th. The stock was sold at an average price of $11.78, for a total value of $193,109.54. Following the completion of the transaction, the general counsel now directly owns 573,478 shares of the company’s stock, valued at $6,755,570.84. This trade represents a 2.78 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 71,245 shares of company stock valued at $843,326. 30.10% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on LQDA shares. HC Wainwright reissued a “buy” rating and set a $29.00 target price on shares of Liquidia in a research note on Thursday, November 14th. Needham & Company LLC reaffirmed a “buy” rating and issued a $19.00 price objective on shares of Liquidia in a research note on Thursday, January 9th. Finally, Wells Fargo & Company started coverage on Liquidia in a research note on Friday, December 20th. They issued an “overweight” rating and a $20.00 price objective for the company. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $25.38.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).